Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03506802
Recruitment Status : Withdrawn (No Participants Enrolled)
First Posted : April 24, 2018
Last Update Posted : July 24, 2020
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : June 25, 2019
Actual Study Completion Date : June 25, 2019